AOD-9604 Peptide

AOD-9604 Peptide Molecular Structure & Chemical Properties

AOD-9604 represents a pioneering approach to peptide-based metabolic research, originally developed in the 1990s at Monash University in Australia as a potential anti-obesity therapeutic. This synthetic peptide consists of the C-terminal fragment (amino acids 176-191) of human growth hormone with an additional tyrosine residue at the N-terminus, designed to retain the lipolytic properties of growth hormone while avoiding its growth-promoting effects. Over 900 subjects participated in clinical trials examining AOD-9604’s safety and efficacy, making it one of the more extensively studied peptide fragments in metabolic research. The peptide’s development was ultimately discontinued in 2007 after a 24-week Phase III trial failed to demonstrate statistically significant weight loss compared to placebo, though research into its regenerative properties has continued.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide contains a disulfide bridge between cysteine residues at positions 7 and 14, contributing to structural stability. This modification distinguishes AOD-9604 from native growth hormone fragments and provides enhanced resistance to enzymatic degradation.

AOD-9604 Mechanism of Action

AOD-9604 exerts its biological effects through mechanisms that remain incompletely characterized, though current evidence suggests beta-3-adrenergic receptor modulation plays a key role in its lipolytic activity. Unlike full-length growth hormone, AOD-9604 does not stimulate IGF-1 production or interact with traditional growth hormone receptors, indicating an independent mechanism of action that has been the subject of ongoing investigation.

Primary Metabolic Pathways

Beta-3-Adrenergic Receptor Modulation

Research in obese mice demonstrated that AOD-9604 increases expression of beta-3-adrenergic receptor RNA in adipose tissue, upregulating levels from those seen in obese animals to levels comparable with lean controls¹. However, studies using beta-3-adrenergic receptor knockout mice revealed a more complex picture:

• Long-term AOD-9604 treatment failed to produce weight loss in beta-3-AR knockout mice
• Acute administration still increased energy expenditure and fat oxidation in knockout mice
• This suggests beta-3-AR expression enhancement contributes to, but does not directly mediate, lipolytic effects

The peptide appears to work through an unidentified receptor mechanism that subsequently influences beta-3-adrenergic signaling pathways.

Lipolysis Stimulation and Lipogenesis Inhibition

Studies in rodent models showed that AOD-9604 peptide preferentially triggers fat release from obese adipocytes more than from lean fat cells². Key metabolic effects include:

• Enhanced lipolysis through activation of fat breakdown pathways independent of growth hormone receptors
• Suppressed lipogenesis reducing conversion of non-fat substrates into stored fat
• Increased fat oxidation and energy expenditure in multiple species models
• No adverse effects on insulin sensitivity or glucose metabolism, unlike full-length growth hormone

Independence from IGF-1 Signaling

A critical distinction of AOD-9604 is its lack of IGF-1 pathway activation³:

• No measurable changes in serum IGF-1 levels in human clinical trials
• Absence of growth-promoting effects on tissues
• No impact on blood glucose regulation or insulin resistance
• Avoidance of typical growth hormone side effects including edema and tissue overgrowth

Metabolic Pathway Modulation

Research indicates AOD-9604 influences energy metabolism through multiple mechanisms:

• Increased whole-body fat oxidation rates in animal models
• Enhanced metabolic rate without stimulant-like effects
• Potential modulation of uncoupling proteins in adipose tissue
• Effects on lipid metabolism that persist beyond plasma clearance

AOD-9604 Research Applications & Key Findings

Metabolic and Obesity Research

Weight Loss and Fat Reduction Studies

Initial clinical trials in obese adults showed promising results, though later studies revealed limitations. A 12-week randomized trial demonstrated³:

• Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group
• Preferential reduction in abdominal and visceral fat deposits
• No adverse effects on carbohydrate metabolism or insulin sensitivity
• Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses

However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007.

Animal Model Obesity Studies

Preclinical research in genetically obese rodents demonstrated more consistent effects²:

• 50% reduction in weight gain in obese Zucker rats treated with 500 mcg/kg oral dosing for 19 days
• Increased lipolytic activity in adipose tissue of treated animals
• Upregulation of beta-3-adrenergic receptors in obese mice to levels comparable with lean controls
• Effects on body composition without adverse metabolic consequences

Cartilage and Joint Health Research

Osteoarthritis and Cartilage Regeneration

Investigations in rabbit osteoarthritis models revealed potential regenerative properties beyond metabolic effects⁵:

• Enhanced cartilage regeneration in collagenase-induced knee osteoarthritis models
• Combined AOD-9604 and hyaluronic acid injections produced superior outcomes to either treatment alone
• Significantly improved morphological and histopathological scores compared to saline controls
• Reduced lameness duration in treated animals

In vitro studies showed AOD-9604 promoted:

• Differentiation of adipose mesenchymal stem cells into bone
• Increased proteoglycan and collagen production in bovine chondrocytes
• Enhanced myoblast differentiation, supporting potential for tissue repair

Safety and Tolerability Research

Human Clinical Safety Data

Six randomized, double-blind, placebo-controlled trials involving approximately 900 subjects established safety profiles³:

• No serious adverse events related to AOD-9604 administration across all studies
• No treatment-related withdrawals in any trial
• Mild, transient side effects limited to injection site reactions and occasional headaches
• No antibody formation detected in subjects tested for immunogenicity

Metabolic Safety Parameters

Critical safety monitoring revealed:

• No changes in IGF-1 levels at any dose or duration tested
• No impairment of glucose tolerance or insulin sensitivity
• No adverse effects on lipid profiles or cardiovascular parameters
• Safety profile indistinguishable from placebo in long-term studies up to 24 weeks

AOD-9604 Pharmacokinetics & Metabolism

Absorption & Distribution

AOD-9604 exhibits unusual pharmacokinetic properties for a peptide, demonstrating activity via multiple administration routes in preclinical models⁴:

• Oral bioavailability confirmed in pig and rodent studies, an uncommon characteristic for peptide compounds
• Rapid systemic distribution following intraperitoneal administration in mice (15-30 minutes)
• Following IV administration in pigs, AOD-9604 and degradation fragments appeared rapidly in plasma
• Oral administration showed slower kinetics but similar degradation product profiles

Distribution studies using radiolabeled peptide (C-14-AOD9604) in rats revealed:

• Elevated concentrations in pineal body and thyroid tissues
• Distribution to all non-CNS tissues examined
• Minimal penetration of blood-brain barrier
• Tissue-specific accumulation patterns suggesting potential targeting mechanisms

Metabolism & Elimination

The metabolic fate of AOD-9604 involves rapid degradation through sequential N-terminal amino acid removal⁴,⁶:

• Plasma half-life of approximately 3 minutes following IV administration in pigs (compared to 21 minutes for full-length growth hormone)
• Sequential amino-terminal truncation represents the primary degradation pathway
• Principal metabolites identified in vivo include -2 amino acid and -3 amino acid fragments
• These truncated fragments retain some reduced in vitro anti-lipogenic activity

A significant pharmacokinetic paradox exists: despite rapid plasma clearance (peptide undetectable at 56 minutes in spiked plasma studies), biological effects on body weight and fat metabolism persist for hours to days. Proposed explanations include:

• Tissue retention of peptide or active metabolites
• Persistent activation of signaling cascades beyond peptide clearance
• Potential for active metabolites with prolonged tissue residence

Excretion Pathways

Limited data on elimination routes indicates:

• Likely renal excretion of peptide fragments based on molecular weight and water solubility
• Potential hepatic contribution to metabolite clearance
• No evidence of accumulation in chronic dosing studies in rats and monkeys
• Degradation products eliminated without evidence of toxic metabolite formation

The dramatic disconnect between three-minute plasma half-life and prolonged metabolic effects remains one of the most intriguing and poorly understood aspects of AOD-9604 pharmacology, requiring further mechanistic investigation.

AOD-9604 Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse AOD-9604 doses across species and administration routes:

• Rodent studies: 250-500 mcg/kg orally or intraperitoneally was most common for obesity research
• Rabbit models: 0.25 mg per joint for osteoarthritis studies (intra-articular injection)
• Pig pharmacokinetic studies: 1.5 mg/kg IV and 2 mg/kg oral for metabolism characterization
• Human clinical trials: Oral doses of 0.25-10 mg daily; IV doses of 25-400 mcg/kg for safety studies

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant differences in metabolism, pharmacokinetics, receptor expression, peptide degradation rates, and tissue distribution patterns. Species-specific factors profoundly influence both efficacy and safety profiles.

Administration Routes in Research

Multiple delivery methods have been investigated across various research applications:

• Oral administration – Uniquely effective for AOD-9604 unlike most peptides; demonstrated bioavailability in multiple species; used in long-term human clinical trials
• Intravenous injection – Used primarily for pharmacokinetic characterization and acute dosing studies in humans
• Intraperitoneal injection – Standard route for chronic rodent studies; reliable systemic delivery
• Subcutaneous injection – Investigated in some metabolic studies and currently used in research settings
• Intra-articular injection – Applied in osteoarthritis models for localized cartilage regeneration effects

Common Model Organisms

AOD-9604 has been studied across multiple species for various research applications:

• Mice – ob/ob and beta-3-AR knockout strains; primary models for obesity and mechanistic studies
• Rats – Obese Zucker rats; used extensively for metabolic and safety studies
• Rabbits – New Zealand White rabbits; employed in osteoarthritis and cartilage regeneration research
• Pigs – Used for pharmacokinetic profiling and oral bioavailability studies
• Cynomolgus monkeys – 9-month chronic toxicology studies via oral gavage
• Human subjects – Approximately 900 participants across six clinical trials examining safety and efficacy

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite over 25 years of research and extensive clinical testing, AOD-9604 faces substantial evidence gaps that have prevented therapeutic development.

Clinical Efficacy Uncertainties

The most significant limitation is the failure to demonstrate consistent efficacy in human applications:

• Discontinued clinical development in 2007 after 24-week Phase III trial showed insufficient weight loss
• Inconsistent dose-response relationship, with higher doses paradoxically less effective than lower doses
• Failure to produce clinically meaningful results when combined with diet and exercise interventions
• No peer-reviewed publications demonstrating sustained weight loss or metabolic benefits in humans

Mechanistic Understanding Gaps

Fundamental aspects of AOD-9604’s mechanism remain unclear despite extensive research:

• Primary receptor target unidentified after decades of investigation
• Relationship between 3-minute plasma half-life and prolonged biological effects unexplained
• Role of metabolites versus parent peptide in mediating effects unknown
• Tissue-specific mechanisms and distribution patterns incompletely characterized

Long-Term Safety Considerations

Critical safety questions remain unanswered beyond the 24-week trial duration:

• Chronic use effects beyond 6 months completely unstudied even in animal models
• Potential long-term metabolic adaptations or tolerance development unknown
• Effects on reproductive function and development inadequately characterized
• Interaction potential with common medications unexamined

Regulatory & Competitive Sport Status

FDA Position

AOD-9604 has never received FDA approval for any indication:

• Not approved for human therapeutic use in the United States
• Not recognized as Generally Recognized As Safe (GRAS) for dietary supplement use (contrary to some marketing claims)
• Not legally available for medical compounding in the United States
• Clinical development terminated by sponsor company in 2007 due to lack of efficacy

The FDA has not issued specific guidance on AOD-9604, but it falls under unapproved new drug regulations and cannot be legally marketed for human consumption.

WADA Prohibition

The World Anti-Doping Agency explicitly prohibits AOD-9604 for competitive athletes⁹:

• Listed under Section S0 (Non-Approved Substances) and S2.2.3 (Growth Hormone Fragments)
• Prohibited at all times (both in-competition and out-of-competition)
• No Therapeutic Use Exemptions (TUEs) available
• Detection methods developed and implemented in anti-doping laboratories worldwide

WADA’s 2013 statement clarified that AOD-9604 “is a substance still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world.”

Research Classification: AOD-9604 is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Heffernan, M., Summers, R.J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W.J., & Ng, F.M. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-3-AR knock-out mice. Endocrinology, 142(12), 5182-5189. PubMed
   
2. Ng, F.M., Sun, J., Sharma, L., Libinaki, R., Jiang, W.J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274-278. PubMed
   
3. Stier, H., Amann, S., & Baumuller, M. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 3(1-2), 10-15.
4. Moré, M., & Koren, E. (2014). Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. Journal of Endocrinology and Metabolism, 4(1-2), 87-95.
5. Kwon, D.R., & Park, G.Y. (2015). Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical & Laboratory Science, 45(4), 426-432. PubMed
   
6. Cox, H.D., Smeal, S.J., Hughes, C.M., Cox, J.E., & Eichner, D. (2015). Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis, 7(1), 31-38. PubMed
   
7. Kim, S.B., Kwon, D.R., Kwak, H., Shin, Y.B., Han, H.J., Lee, J.H., & Choi, S.H. (2010). Additive effects of intra-articular injection of growth hormone and hyaluronic acid in rabbit model of collagenase-induced osteoarthritis. Journal of Korean Medical Science, 25(5), 776-780. PubMed
   
8. Heffernan, M.A., Thorburn, A.W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M.J., & Ng, F.M. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity, 25(10), 1442-1449. PubMed
   
9. World Anti-Doping Agency. (2013). WADA statement on substance AOD-9604. Retrieved from https://www.wada-ama.org
10. Halford, J.C. (2006). Obesity drugs in clinical development. Current Opinion in Investigational Drugs, 7(4), 312-318.

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. AOD-9604 is intended for laboratory research use only.